



BioMS Medical

BioMS Medical Corp. is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with an emphasis on the treatment of multiple sclerosis (MS). Our lead technology, dirucotide, is being evaluated in two pivotal phase III clinical trials in secondary progressive MS (SPMS)—MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into an exclusive worldwide licensing and development agreement with Eli Lilly and Company.

Dirucotide

- Designed for progressive MS patients
- Demonstrated effect on MS disease progression in two phase II trials
- The only novel agent in Phase III trials for secondary progressive MS
- Blockbuster potential in a large underserved market
- More than 1,000 patients treated with no safety concerns
- More than 100 patents granted including eight U.S. patents
- Partnered with Eli Lilly and Company
- Pivotal Phase III results expected in the second half of 2009

MS is a progressive disease affecting 2.5 million people

Relapsing Remitting Multiple Sclerosis (RRMS)

~40%
of MS patients

Current treatments focus on increasing time between relapses, not slowing progression.

US \$8.8B
current market

Secondary Progressive Multiple Sclerosis (SPMS)

~40%
of MS patients

Current treatments are only moderately effective and can produce serious side effects.

Equivalent unrealized
blockbuster market potential

About Dirucotide

Dirucotide was developed specifically for the treatment of multiple sclerosis and is based on over 26 years of research. The drug is a synthetic peptide consisting of a sequence of 17 amino acids identical to a portion of human myelin basic protein (MBP), a key component of the nervous system that is the dominant target of the autoimmune attack in most MS patients.

Previous Clinical Trials

The results of a phase II trial and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the *European Journal of Neurology* (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA DR2 and/or DR4 immune response genes (up to 70% of all MS patients). Dirucotide has more than 1,300 combined years of patient treatment experience with no safety concerns to date. Dirucotide has Fast track designation in the U.S.

Delayed median time to disease progression for five years vs. placebo

BioMS & Lilly Partnership

In 2007, BioMS Medical and Eli Lilly and Company (NYSE:LLY) announced a global licensing and development agreement granting Lilly exclusive worldwide rights to dirucotide. Under the terms of the agreement, BioMS Medical received an upfront payment of US\$87 million, a subsequent US\$10 million milestone payment based on a positive interim analysis, as well as potential development and sales milestones of up to US\$400 million and escalating royalties on sales.

Working together for new hope.

Current Clinical Trials

BioMS is conducting two ongoing pivotal clinical trials evaluating the ability of dirucotide to affect disease progression in patients with secondary progressive MS:



A Canadian/European pivotal phase III trial evaluating dirucotide for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in ten countries. To date, there have been ten positive safety reviews from the Data Safety Monitoring Board (DSMB).

Results of MAESTRO-01 expected in the second half of 2009



An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive dirucotide on an un-blinded basis in MAESTRO-02. Of patients who have successfully completed MAESTRO-01 to date, approximately 95 percent have entered the follow-on study.



A U.S. pivotal phase III trial evaluating dirucotide for the treatment of SPMS. The trial is fully recruited with approximately 510 patients enrolled at 68 sites across the U.S. To date, the DSMB has conducted four reviews of the data from this trial and has recommended it continue.

Head Office

BioMS Medical Corp.
8812-60 Avenue
Edmonton, Alberta
Canada T6E 6A6

Contacts

Ryan Giese
VP Corporate Communications
Phone: 780-413-7152
rgiese@biomsmedical.com

Tony Hesby
Executive VP
Phone: 780-413-7152
thesby@biomsmedical.com

Amanda Stadel
Investor Relations Manager
Phone: 780-413-7152
astadel@biomsmedical.com